HBIO Q2 2026: 11% Revenue Growth Driven by CMT and China Expansion, Raising Full-Year Guidance
Harvard Bioscience delivered robust 11% year-over-year revenue growth in Q2, fueled by strong demand in cellular and molecular technology (CMT) and China markets. Operational progress and recurring revenue expansion underpin an upward revision to full-year guidance. Strategic initiatives like Project Viking and Made in China localization are set to enhance margins and competitive positioning in 2027.
Summary
- Commercial Momentum Strengthens: Double-digit growth in CMT and telemetry products drives top-line expansion.
- Operational Discipline Advances: Project Viking manufacturing consolidation and cost control efforts support margin stability.
- Recurring Revenue Focus: Expansion of consumables and software drives recurring revenue to 55% of total sales.
Business Overview
Harvard Bioscience (HBIO) develops and sells life science research tools, focusing on preclinical and cellular and molecular technology (CMT) platforms. The company generates revenue through direct sales and distribution channels across the Americas, Europe, and Asia, with key segments including telemetry, bioprocessing, electroporation, and respiratory inhalation products.
Performance Analysis
In the second quarter of 2026, Harvard Bioscience reported $22.7 million in revenue, marking an 11% increase year-over-year and surpassing guidance expectations. This growth was largely driven by strong demand from contract research organizations (CROs) and solid sales within the CMT portfolio, including notable double-digit expansion in telemetry and electroporation product lines. The China region delivered a remarkable 29% revenue increase, supported by the Made in China localization initiative and distributor partnerships.
Adjusted gross margin was 55.6%, slightly below the prior year’s 56.4%, primarily due to a product and geographic mix shift favoring lower-margin CMT products and increased China sales. Operating expenses rose by $1.2 million, reflecting restored salaries and merit increases, which management views as investments for future leverage. Adjusted EBITDA reached $1.7 million, an 11% improvement over the prior year, with margin stability despite OPEX growth. Cash used in operations was modest at $0.3 million for the first half, impacted by inventory build to support manufacturing transitions.
- Geographic Growth Concentrated in China and Americas: China revenues surged 29%, while Americas grew 13%, driven by CRO demand.
- Recurring Revenue Expansion: Consumables, software licenses, and service contracts increased to 55% of total revenue, advancing toward a 60% target.
- Normalized Cost Structure: Operating expenses reflect strategic investments in sales and marketing, offsetting margin gains but positioning for future leverage.
Overall, Harvard Bioscience’s financial performance reflects successful execution of its strategic focus on high-growth customer segments and product portfolios, setting a foundation for sustainable improvement.
Executive Commentary
"We delivered a strong quarter anchored by 11% top-line growth, reflective of stronger demand and an improved environment across our key customer channels. We are seeing solid commercial traction across our telemetry and cellular and molecular technology products, driven by our AAA and electroporation businesses, and strong engagement from researchers utilizing our preclinical platform."
John Duke, President and Chief Executive Officer
"Revenue of $22.7 million was up 11% year-over-year, exceeding our guidance range. Adjusted EBITDA grew 11% to $1.7 million, reaching the high end of our outlook. We continue to focus on expanding recurring revenue opportunities, which improved to 55% of revenue in the first half."
Mark Frost, Chief Financial Officer
Strategic Positioning
1. Focus on High-Growth CMT and Preclinical Portfolios
Harvard Bioscience concentrates on cellular and molecular technology platforms, including telemetry implants, electroporation, and AAA bioprocessing. These areas are driving double-digit growth and increasing recurring revenue through consumables and software, enhancing customer stickiness and margin profiles.
2. Geographic Expansion with China Localization
The Made in China initiative is accelerating regional sales, with localized BTX product lines gaining traction. Distributor-led sales in China have contributed a 29% revenue increase, positioning HBIO to capitalize on growing biopharma and CRO activity in the Asia-Pacific region.
3. Operational Efficiency via Project Viking
Manufacturing footprint consolidation under Project Viking is on track, with two product lines transitioned and two more planned for Q3. Anticipated to deliver $3 million in cost savings in 2027 and $4 million annually thereafter, this initiative supports margin expansion and operational scalability.
4. Recurring Revenue as a Long-Term Growth Lever
HBIO’s strategy to increase recurring revenue through high-margin consumables, annual software licenses, and service contracts is progressing, with recurring revenue rising to 55% of total sales in H1 2026. This shift improves revenue predictability and profitability.
5. Commercial Team Optimization
The recent appointment of an SVP of Commercial focuses the sales organization on highest-growth opportunities, particularly MPI platforms, AAA bioprocessing, and expanding market share within pharmaceutical, biotech, and CRO accounts.
Key Considerations
The second quarter highlights Harvard Bioscience’s disciplined execution and strategic focus, but investors should consider the following:
- Product Mix Impact on Margins: Higher sales of lower-margin CMT products and China sales temporarily compress gross margins.
- Investment in Sales and Marketing: Restored compensation and merit increases increase operating costs but aim to drive future revenue leverage.
- Inventory Build for Manufacturing Transitions: Elevated inventory levels support Project Viking but increase working capital usage.
- Debt and Interest Expense: Net debt rose to $33.5 million with higher interest costs, requiring monitoring of leverage and cash flow.
- Academic Market Recovery: Early signs of improvement in academic funding may support growth in this segment in H2 2026.
Risks
Risks include potential margin pressure from product mix shifts, delays in manufacturing consolidation, and challenges in finding subtenants for the Holliston facility. Additionally, macroeconomic factors affecting biopharma spending and academic funding could impact demand. Currency fluctuations and geopolitical tensions may also affect international sales, especially in China.
Forward Outlook
For the third quarter of 2026, Harvard Bioscience expects:
- Revenue between $21.0 million and $22.6 million, implying mid-single-digit year-over-year growth.
- Adjusted gross margin between 56% and 58%.
- Adjusted EBITDA between $1.5 million and $2.5 million, reflecting improving profitability.
For full-year 2026, the company raised revenue growth guidance to 3% to 5%, adjusted gross margin guidance to 57% to 59%, and reaffirmed adjusted EBITDA growth of 6% to 10%. Management anticipates stronger EBITDA flow-through in the second half, driven by revenue growth and cost discipline, with Q4 historically the strongest quarter.
Takeaways
Harvard Bioscience’s Q2 results underscore the company’s strategic pivot toward higher-growth, higher-margin product lines and geographic expansion, supported by operational initiatives designed to enhance profitability and cash flow.
- Commercial Execution Drives Growth: Strong double-digit growth in CMT and telemetry products, particularly in China and CRO channels, validates the company’s focused sales strategy.
- Operational Investments Signal Confidence: Increased OPEX and inventory build reflect deliberate investments in sales capacity and manufacturing readiness to support future scaling.
- Margin Expansion Hinges on 2027 Initiatives: Project Viking savings and recurring revenue growth are critical to improving adjusted gross margin beyond the current 57% to 59% guidance range.
Conclusion
Harvard Bioscience’s second quarter 2026 performance demonstrates tangible progress in executing its strategic priorities, driving top-line growth and operational improvements. The raised full-year guidance and ongoing initiatives position the company for sustainable growth and margin expansion in the coming years.
Industry Read-Through
HBIO’s results reflect broader trends in the life sciences sector, including increased demand for preclinical research tools, the rising importance of recurring revenue through consumables and software, and regional growth driven by localized manufacturing. Competitors and investors should monitor how Project Viking-style operational consolidations and China market penetration strategies influence margin trajectories and competitive dynamics across the industry.